Combination Therapy in Patients With Relapsing-Remitting Multiple Sclerosis (MS)CombiRx
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is for a randomized clinical trial (RCT) to determine if the combined use of interferon
beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent
used individually in patients with relapsing-remitting (RR) multiple sclerosis (MS).
Phase:
Phase 3
Details
Lead Sponsor:
Fred Lublin
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)